(Q37970526)

26 August 2017

title

Enlarging the "Audacious Goal": elimination of the world's high prevalence neglected tropical diseases (English)

1 reference

26 August 2017

1

1 reference

26 August 2017

language of work or name

English

0 references

publication date

19 December 2011

1 reference

26 August 2017

1 reference

26 August 2017

volume

29 Suppl 4

1 reference

26 August 2017

page(s)

D104-10

1 reference

Rescuing the bottom billion through control of neglected tropical diseases

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Mass drug administration and integrated control for the world's high-prevalence neglected tropical diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

"Manifesto" for advancing the control and elimination of neglected tropical diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Epidemiology and transmission dynamics of Ascaris lumbricoides in Okpo village, rural Burma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

The population biology and control of Ascaris lumbricoides in a rural community in Iran

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Developing vaccines to combat hookworm infection and intestinal schistosomiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Oral drug therapy for multiple neglected tropical diseases: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Antigen selection for future anti-Trichuris vaccines: a comparison of cytokine and antibody responses to larval and adult antigen in a primary infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Which new approaches to tackling neglected tropical diseases show promise?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Parasites and poverty: the case of schistosomiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

From innovation to application: Social–ecological context, diagnostics, drugs and integrated control of schistosomiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Schistosomiasis elimination: lessons from the past guide the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Africa is desperate for praziquantel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Schistosomiasis in Africa: an emerging tragedy in our new global health decade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Multivalent anthelminthic vaccine to prevent hookworm and schistosomiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Lymphatic filariasis and onchocerciasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Elimination of lymphatic filariasis: do we have the drugs to complete the job?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Towards a recombinant antigen vaccine against Onchocerca volvulus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

The elimination of Chagas' disease from Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Eliminating Chagas disease: challenges and a roadmap

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Vaccination approaches against Trypanosoma cruzi infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

The relationship between leishmaniasis and AIDS: the second 10 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Optimized subunit vaccine protects against experimental leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Intranasal immunization with Leish-111f induces IFN-gamma production and protects mice from Leishmania major infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Immunity to distinct sand fly salivary proteins primes the anti-Leishmania immune response towards protection or exacerbation of disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Leprosy elimination: not as straightforward as it seemed

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

7 January 2021

The antipoverty vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

A handful of 'antipoverty' vaccines exist for neglected diseases, but the world's poorest billion people need more

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

The health impact of polyparasitism in humans: are we under-estimating the burden of parasitic diseases?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

New antipoverty drugs, vaccines, and diagnostics: a research agenda for the US President's Global Health Initiative (GHI).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

Neglected Tropical Disease Control in the “Post-American World”

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.024

10.1016/J.VACCINE.2011.06.024

7 January 2021

Identifiers

DOI

1 reference

26 August 2017

1 reference